Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof

A technology for fatty liver disease and active ingredients, used in drugs for the treatment of chronic liver disease, in the field of active ingredients in traditional Chinese medicine, and can solve problems such as difficulty in understanding the ingredients contained, complex ingredients, controllability of preparations, and stability problems

Active Publication Date: 2014-05-21
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF3 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no matter the traditional Chinese medicine compound or a single active ingredient has its shortcomings
Due to the complex composition of traditional Chinese medicine compound, it is difficult to understand its ingredients, which makes its preparations have certain controllability and stability problems. Therefore, how to "remove the rough and extract the essence" of traditional compound prescriptions while maintaining the advantages of TCM compound prescriptions in the treatment of complex diseases is a major problem, and it is also one of the breakthrough directions in the research of TCM anti-nonalcoholic fatty liver drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof
  • Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof
  • Compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] According to the weight ratio of 67.2:10 to 67.2:0.2, the active ingredients of traditional Chinese medicine geniposide and chlorogenic acid are taken, and the compound preparation for anti-nonalcoholic fatty liver disease is prepared according to the conventional method. Among the active ingredients of the traditional Chinese medicine, geniposide ( Geniposide) is derived from Gardenia, which can be obtained through conventional extraction methods or commercial purchases; chlorogenic acid (Chlorogenic acid) is derived from the traditional Chinese medicine Yin Chen, which can be obtained through conventional extraction methods or commercial purchases.

[0025] More specifically, the compound preparation of the present invention can be made into commonly used clinical preparations according to conventional methods, and the dosage forms include oral solid preparations such as granules, tablets, and capsules.

Embodiment 2

[0027] Regression analysis of rat non-alcoholic fatty liver model induced by high-fat diet and uniform design method to obtain the corresponding optimal formula for reducing liver triglyceride content

[0028] 1. Materials

[0029] (1) Animals: Wistar male rats, clean grade, weighing (160±10) g, provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences;

[0030] 53 SD male rats, weighing 150±10g, clean grade, purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences;

[0031](2) Main reagents and drugs: Polydatin is derived from Polygonum cuspidatum, batch number: RE090703, chlorogenic acid is derived from capillary capillary, batch number: GY0900705, geniposide is derived from gardenia, batch number: CY101018, curcumin (curcumin) is derived from turmeric, batch number: CU090912, Rhizoma Atractylodis Macrocephalae is derived from Atractylodes macrocephalae, batch number: GY090510, and the above drugs were purchased from Xi'an...

Embodiment 3

[0050] Example 3 Use the rat fatty liver model induced by high-fat diet to verify the curative effect of the screened ZL formula

[0051] 1. Materials

[0052] (1) Animals: SD male rats, clean grade, weighing (170±10) g, provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences;

[0053] (2) Main reagents and drugs: the control drug rosiglitazone was purchased from GlaxoSmithKline (Tianjin) Co., Ltd. (batch number: 10045192), geniposide (batch number: 111226) and chlorogenic acid (batch number: 111209) were purchased from Shanghai Ronghe Pharmaceutical Technology Development Co., Ltd. ALT, AST and FFA detection kits were purchased from Nanjing Jiancheng Bioengineering Institute.

[0054] 2. Method

[0055] (1) Grouping and modeling 54 SD rats were randomly divided into normal group (9 rats) and modeling group (45 rats). The modeling method was the same as "Example 1", and the modeling components were made 4 weeks after modeling The model group ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of traditional Chinese medicines, relates to a compound traditional Chinese medicinal effective component preparation for resisting alcoholic fatty liver disease and application thereof, and in particular relates to a compound traditional Chinese medicinal component preparation comprising geniposide and chlorogenic acid and application thereof. The compound preparation is prepared from geniposide and chlorogenic acid, and can be processed into clinical common preparations by a conventional method, including granules, tablets, capsules and other oral solid preparations. Animal experiments indicate that the compound preparation can remarkably reduce the content of triglyceride of liver tissues of a rat model, and reduce the degeneration degree of liver fat and liver damage degree. The effects of the compound preparation are superior to those of single component. The compound preparation can be used for improving the effect of resisting alcoholic fatty liver, effectively preventing development of non-alcoholic fatty liver, and can be used for treating and preventing non-alcoholic fatty liver, chronic liver damage and other symptoms.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine, and relates to a drug for improving the anti-nonalcoholic fatty liver disease, in particular to a compound and application of active ingredients of traditional Chinese medicine for anti-nonalcoholic fatty liver disease, especially to a compound composed of geniposide and chlorogenic acid The composition of the active ingredient compound of traditional Chinese medicine and its application in medicine for treating chronic liver disease. Background technique [0002] The prior art discloses that non-alcoholic fatty liver disease (NAFLD) is a genetic-environment-metabolic stress-related liver disease, including simple fatty liver (NAFL) and steatohepatitis (NASH) and liver cirrhosis evolved therefrom. According to reports, at present, the prevalence of NAFLD is about 30% in western developed countries; in my country, due to changes in living habits and diet structure, the incidence is on t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K31/216A61P1/16
Inventor 胡义扬冯琴彭景华唐亚军孟胜喜刘平
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com